share_log

Evogene Q2 Revenue Grows 131%, Here Is What You Need To Know

Evogene Q2 Revenue Grows 131%, Here Is What You Need To Know

Evogene第二季度收入增长131%,以下是您需要知道的
Benzinga Real-time News ·  2022/08/31 11:32
Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales of Lavie Bio's Thrivus product (previously branded as Result) and sales of Canonic products in the Israeli market.
Evogene Ltd.纳斯达克股票代码:EVGN)2022年第二季度收入为312,000美元,与去年同期的135,000美元相比增长了131%。收入主要来自于最初的销售Lavie Bio's 特里弗斯产品(以前的品牌为结果)和销售正典以色列市场上的产品。
Q2 2022 Financial Highlights
2022年第二季度财务亮点
Net loss was $9.8 million in comparison to a net loss of $6.9 million in the same period in the previous year. R&D expenses for the quarter, which are reported net of non-refundable grants received, were $5.4 million, in comparison to $5.0 million in the same period the previous year. The increase...
NET的损失为980万美元相比之下,去年同期净亏损690万美元。 研发费用在本季度,报告的净额是收...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发